Zura Bio Limited
ZURAZura Bio Limited is a clinical-stage biotechnology company focused on developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases.
Earnings
Next report
Date not yet announcedCompetitors
By market cap
Profile
Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases. The company identifies immune-mediated diseases where translational and clinical evidence supports specific biological pathways, targeting conditions with significant unmet medical needs. Its core strategy involves advancing multi-target and single-target antibody-based therapies to achieve durable disease control.
A clinical-stage developer of differentiated bispecific and monoclonal antibodies targeting IL-17A, BAFF, IL-7Rα, and IL-33 pathways.
FAQ
- What is Zura Bio Limited's market cap?
- Zura Bio Limited (ZURA) has a market capitalization of $370.9M and trades on NASDAQ.
- Who are Zura Bio Limited's competitors?
- Zura Bio Limited's key competitors include Amgen Inc., AbbVie Inc., Rezolute, Inc. Common Stock (NV), and others. These companies compete in similar markets and product categories.
- Who does Zura Bio Limited partner with?
- Zura Bio Limited's notable partners include Eli Lilly and Company, Pfizer Inc., Lonza Sales AG, and others.
- What subsidiaries does Zura Bio Limited have?
- Zura Bio Limited's subsidiaries include ZB17 LLC, Z33 Bio Inc., Zura Bio UK.
- Where is Zura Bio Limited headquartered?
- Zura Bio Limited is headquartered in United States of America and employs approximately 15 people. It has been publicly traded since 2023.